Pulmonx Co. (NASDAQ:LUNG – Get Free Report) insider Geoffrey Beran Rose sold 4,586 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total transaction of $30,726.20. Following the completion of the transaction, the insider now owns 295,433 shares in the company, valued at approximately $1,979,401.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Geoffrey Beran Rose also recently made the following trade(s):
- On Monday, June 24th, Geoffrey Beran Rose sold 1,184 shares of Pulmonx stock. The shares were sold at an average price of $6.16, for a total transaction of $7,293.44.
Pulmonx Stock Up 5.3 %
Shares of Pulmonx stock opened at $7.31 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84. The business has a 50-day moving average of $6.92 and a 200-day moving average of $7.82. The company has a market capitalization of $283.74 million, a PE ratio of -4.75 and a beta of 0.63.
Analyst Ratings Changes
Read Our Latest Analysis on LUNG
Institutional Investors Weigh In On Pulmonx
A number of hedge funds have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC purchased a new position in shares of Pulmonx during the 2nd quarter valued at approximately $477,000. Mackenzie Financial Corp acquired a new stake in Pulmonx in the second quarter valued at $102,000. Deerfield Management Company L.P. Series C boosted its stake in Pulmonx by 134.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 47,539 shares of the company’s stock valued at $301,000 after acquiring an additional 27,250 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Pulmonx during the 2nd quarter valued at $37,000. Finally, Squarepoint Ops LLC grew its holdings in Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after acquiring an additional 104,432 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
See Also
- Five stocks we like better than Pulmonx
- How to Invest in Small Cap Stocks
- Fed Rate Cuts on the Horizon: Why These 2 Stocks Stand to Benefit
- How to Invest in the Best Canadian Stocks
- MarketBeat Week in Review – 9/2 – 9/6
- What is the Nikkei 225 index?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.